Symphogen A/S has reached agreement with its investors on a €67.5 million convertible debt facility that will help finance the clinical development of an antibody drug candidate for patients with metastatic colorectal cancer. The funds will also support development of two preclinical cancer compounds.
Switzerland-based Basilea Pharmaceutica Ltd has filed a registration document with the US Securities and Exchange Commission (SEC) in preparation for a listing of its shares on the Nasdaq over-the-counter market.
Spain-based Minoryx Therapeutics sl, which is developing drugs for rare diseases, has raised €19.4 million in a Series A funding round to progress its lead candidate into the clinic for multiple disorders of the central nervous system.
Luxendo GmbH, a start-up medical technology company, has raised €6 million in a Series A funding round to commercialise new microscope technology that enables researchers to create high-resolution images of tissue and living organisims.
An undisclosed amount of seed funding has been provided by two UK investors for a start-up gene therapy company that is working on a concept for preventing nerve damage in glaucoma, the leading cause of irreversible blindness worldwide.
The Swedish specialty pharmaceutical company Pharmalink AB has raised SEK 100 million (€10.5 million) to prepare for a Phase 3 development programme of its candidate product for primary IgA nephropathy, an inflammatory disease of the kidney.
The Wales Life Science Fund has led a €12 million Series B funding round for drug developer Apitope in order to enable to company to progress its pipeline of peptide-based therapeutics directed at autoimmune and allergic diseases.
Austria-based Nabriva Therapeutics AG has raised $92.25 million gross in an initial public offering (IPO) of its shares on the Nasdaq market to finance development of its portfolio of anti-infective medicines. Leerink Partners LLC and RBC Capital Markets LLC jointly managed the offering.
Replimune Ltd, a UK start-up, has raised $30 million in Series A finance to develop therapeutics based on the use of oncolytic viruses, or viruses that infect and destroy cancer cells. The funding round is being led by Atlas Venture with participation from Forbion Capital Partners and Omega Funds.
Allergy Therapeutics Plc reported strong growth in European sales for the year to 30 June, giving it a platform for the future launch of its candidate short-course vaccine against grass allergy, Pollinex Quattro Grass.